Bank of New York Mellon Corp - ALLOGENE THERAPEUTICS INC ownership

ALLOGENE THERAPEUTICS INC's ticker is ALLO and the CUSIP is 019770106. A total of 114 filers reported holding ALLOGENE THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is 1.10 and the average weighting 0.7%.

Quarter-by-quarter ownership
Bank of New York Mellon Corp ownership history of ALLOGENE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$985,281
-35.8%
310,814
+0.6%
0.00%
Q2 2023$1,535,163
-11.3%
308,886
-11.8%
0.00%
Q1 2023$1,729,835
-10.8%
350,169
+13.5%
0.00%
Q4 2022$1,939,974
-37.7%
308,422
+6.9%
0.00%
-100.0%
Q3 2022$3,115,000
+10.0%
288,522
+16.2%
0.00%0.0%
Q2 2022$2,831,000
+3.9%
248,381
-17.0%
0.00%0.0%
Q1 2022$2,726,000
-38.8%
299,247
+0.2%
0.00%0.0%
Q4 2021$4,456,000
-45.6%
298,678
-6.3%
0.00%
-50.0%
Q3 2021$8,193,000
+11.3%
318,805
+12.9%
0.00%
+100.0%
Q2 2021$7,363,000
-6.1%
282,337
+27.1%
0.00%
-50.0%
Q1 2021$7,841,000
+35.0%
222,150
-3.5%
0.00%
+100.0%
Q4 2020$5,810,000
-31.0%
230,166
+3.1%
0.00%
-50.0%
Q3 2020$8,417,000
-13.9%
223,219
-2.2%
0.00%
-33.3%
Q2 2020$9,777,000
+217.0%
228,329
+43.9%
0.00%
+200.0%
Q1 2020$3,084,000
-24.2%
158,666
+1.3%
0.00%0.0%
Q4 2019$4,068,000
+1.0%
156,590
+6.0%
0.00%0.0%
Q3 2019$4,028,000
+12.1%
147,789
+10.4%
0.00%0.0%
Q2 2019$3,593,000
+59.2%
133,810
+71.4%
0.00%0.0%
Q1 2019$2,257,000
+139.9%
78,067
+123.3%
0.00%
Q4 2018$941,00034,9680.00%
Other shareholders
ALLOGENE THERAPEUTICS INC shareholders Q1 2020
NameSharesValueWeighting ↓
Vida Ventures Advisors, LLC 1,798,163$45,386,0009.32%
TPG Group Holdings (SBS) Advisors, Inc. 18,716,306$472,400,0005.23%
Wildcat Capital Management, LLC 1,515,524$38,252,0004.81%
REGENTS OF THE UNIVERSITY OF CALIFORNIA 900,143$22,720,0003.28%
Coastal Bridge Advisors, LLC 385,824$9,738,0001.93%
Casdin Capital, LLC 945,000$23,852,0000.71%
DSAM Partners (London) Ltd 208,798$5,270,0000.62%
BAINCO INTERNATIONAL INVESTORS 152,839$3,858,0000.44%
Pier Capital, LLC 152,071$3,838,0000.41%
Woodline Partners LP 567,539$14,325,0000.38%
View complete list of ALLOGENE THERAPEUTICS INC shareholders